TEVA-LIOTHYRONINE TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

şimdi satın al

Ürün özellikleri Ürün özellikleri (SPC)
20-11-2019

Aktif bileşen:

LIOTHYRONINE (LIOTHYRONINE SODIUM)

Mevcut itibaren:

TEVA CANADA LIMITED

ATC kodu:

H03AA02

INN (International Adı):

LIOTHYRONINE SODIUM

Doz:

5MCG

Farmasötik formu:

TABLET

Kompozisyon:

LIOTHYRONINE (LIOTHYRONINE SODIUM) 5MCG

Uygulama yolu:

ORAL

Paketteki üniteler:

15G/50G

Reçete türü:

Prescription

Terapötik alanı:

THYROID AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0102421001; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2019-11-21

Ürün özellikleri

                                _ _
_Teva-Liothyronine Tablets _
_Page 1 of 17_
PRODUCT MONOGRAPH
Pr
TEVA-LIOTHYRONINE
Liothyronine Sodium Tablets
5 mcg and 25 mcg liothyronine as liothyronine sodium
USP
Hypothyroidism Therapy
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Date of Approval:
November 20, 2019
Submission Control No: 217318
_ _
_Teva-Liothyronine Tablets _
_Page 2 of 17_
TABLE OF CONTENTS
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................7
DRUG/LABORATORY TEST INTERACTIONS
.............................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION
............................................................................................................................12
CLINICAL PHARMACOLOGY
......................................................................................12
SUPPLY
.............................................................................................................................15
COMPOSITION
................................................................................................................15
PART III: CONSUMER INFORMATION
......................................................................16
_ _
_Teva-Liothyronine Tablets _
_Page 3 of 17_
Pr
TEVA-LIOTHYRONINE
liothyronine sodium
INDICATIONS AND CLINICAL USE
TEVA-LIOTHYRONINE is 
                                
                                Belgenin tamamını okuyun
                                
                            

Diğer dillerdeki belgeler

Ürün özellikleri Ürün özellikleri Fransızca 20-11-2019

Bu ürünle ilgili arama uyarıları

Belge geçmişini görüntüleyin